Abstract: Objective To invsetigate the effects of Tirofiban Hydrochloride on platelet aggregation rate and major adverse cardiovascular events (MACE) in patients with non-ST-segment elevation myocardial infarction. Methods 99 patients who were diagnosed as NSTE-AMI were randomly divided into Tiroifban Hydrochloride group (group A, 50 cases) and the routine treatment group (group B, 49 cases). Group A was treated with Tiroifban Hydrochloride, administered as a dose of 0.4 μg/(kg · min) over a 30-minute period and followed by a 72-hour infusion of 0.1 μg/(kg· min), in addition to routine treatment. as group B was treated with routine treatment. Platelet aggregation rates were measured before treatment and after 72-hour treatment. Patients were followed up for 30 d, the incidence of major adverse cardiovascular events and the adverse reactions were observed. Results The platelet aggregation rate levels were decreased more obviously in group A after treatment for 72 hours (P<0.05). After 30 days, the incidence of major adverse cardiovascular events was lower in group A than that in group B(P<0.05). There was no severe haemorrhage in both groups. Conclusion Early use of Tirofiban Hydrochloride can reduce the platelet aggregation rate obveriously in patients with non-ST-segment elevation myocardial infarction, which can reduce the incidence of major adverse cardiovascular events. Tiroifban Hydrochloride is effective and safe in clinical practice.

Key words: acut-non-ST-segment elevation myocardial infarction, Tiroifban Hydrochloride, platelet aggregation rate, major adverse cardiovascular events